Reuss and colleagues (37) showed that MPNST cell lines with complete NF1 deficiency were sensitive to TRAIL-induced cell death that was critically dependent on MYC. Thus, targeting dysregulated MYC expression using BRD4 inhibitors may represent a therapeutic opportunity in NF1-associated MPNST (38). The gene discussed is NF1; the disease is malignant peripheral nerve sheath tumor.